Carcinoma, Hepatocellular Clinical Trials

295 clinical trials for Carcinoma, Hepatocellular across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• National Liver Cancer Screening Trial — RECRUITING · PHASE4
• Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. — RECRUITING · PHASE1
• A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE2
• Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI — RECRUITING · NA
• Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study — RECRUITING · NA
• Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer — RECRUITING · NA
• A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors — RECRUITING · PHASE1
• Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer — RECRUITING · PHASE4
• Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma — RECRUITING · PHASE2
• Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma — RECRUITING
• 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia — RECRUITING · NA
• A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy — RECRUITING · PHASE2
• Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC — RECRUITING · NA
• A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers — RECRUITING · PHASE2
• A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. — RECRUITING · PHASE2
• A Study of PTX-9908 Injection for Non-resectable HCC with TACE — RECRUITING · PHASE1
• Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma — RECRUITING
• Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection — RECRUITING · PHASE2
• Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) — RECRUITING
• ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE1
• CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure — NOT_YET_RECRUITING
• Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors — COMPLETED
• A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma — COMPLETED · PHASE2
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery — COMPLETED · PHASE2
• A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation — COMPLETED · PHASE3
• A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma — COMPLETED · PHASE2
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) — COMPLETED · PHASE3
• Paediatric Hepatic International Tumour Trial — ACTIVE_NOT_RECRUITING · PHASE3
• Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants — COMPLETED
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) — COMPLETED
• Atezolizumab Plus Bevacizumab With HCC and HBV Infection — ACTIVE_NOT_RECRUITING · NA
• Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients — NOT_YET_RECRUITING · PHASE2
• Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial — NOT_YET_RECRUITING · PHASE2
• Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis — COMPLETED · PHASE3
• Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion — TERMINATED · PHASE2
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — ACTIVE_NOT_RECRUITING · PHASE1
• Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response — TERMINATED · NA
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 — TERMINATED · PHASE3
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) — COMPLETED · PHASE3
• A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer — COMPLETED · PHASE1
• A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma — COMPLETED · PHASE1
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors — COMPLETED · PHASE1
• Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) — COMPLETED · PHASE3
• A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista — COMPLETED · PHASE3
• Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma — TERMINATED · NA
• Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB — NOT_YET_RECRUITING · PHASE4
• CT Imaging for Guiding PA-TACE for HCC — COMPLETED
• RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System — COMPLETED · NA
• A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy — TERMINATED · PHASE3
• A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma — WITHDRAWN · PHASE2

Refine this search